Eli Lilly promises five new approvals in next two years with Alzheimer’s at the forefront
Eli Lilly set an ambitious goal before its investor day on Wednesday, promising to have new five approved drugs in the next two years.
Those five will be led by donanemab, the anti-amyloid antibody for Alzheimer’s disease for which Lilly expects to complete a rolling submission in 2022’s first quarter. Lilly is attempting to use the same accelerated approval pathway controversially granted to Biogen for aducanumab earlier this year and plans to pit the drugs head-to-head in a Phase III study.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.